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A proportion of patients with hormone receptor-positive locally advanced or metastatic breast cancer
will not have received prior endocrine therapy. However, there are limited clinical data speciﬁcally in
these patients. We conducted a review of randomized phase II and III clinical studies of anastrozole,
letrozole, exemestane, palbociclib, and fulvestrant to determine the evidence base supporting use of
speciﬁc endocrine therapies in this patient population. From our ﬁndings, there is a paucity of clinical
studies in patients with endocrine therapy-naïve disease; however, it appears that ﬁrst-line treatment
effects are consistent between patients who have and have not received prior endocrine treatment.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Standard treatment for patients with localized hormone
receptor-positive breast cancer, which accounts for the majority of
cases at diagnosis, includes endocrine therapy. Consequently, few
patients with locally advanced or metastatic disease will not have
received prior endocrine therapy and may present with: (1) de
novo advanced disease and have not received prior systemic
treatment; (2) advanced disease and have not been treated with
endocrine therapy; and (3) recurrent metastatic breast cancer and
have not received treatment with adjuvant endocrine therapy.Materials and methods
We performed a literature review of randomized studies of
aromatase inhibitors (anastrozole, letrozole, and exemestane), a
cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib), and a
selective estrogen receptor degrader (fulvestrant) to determine the
level of evidence supporting the use of speciﬁc endocrine therapiesyclin-dependent kinase; CI,
an epidermal growth factor
ot applicable; OR, objective
survival; PgR, progesterone
), slopeztarruella@gmail.com
anz).
Ltd. This is an open access article uin patients with locally advanced or metastatic hormone receptor-
positive disease who have not received any prior endocrine
therapy.Results
Summaries of the studies identiﬁed in our literature review are
presented in Table 1. Two phase III, double-blind studies of anas-
trozole vs. tamoxifen as ﬁrst-line treatment were identiﬁed. In one
study, time to progression (TTP) with anastrozole was at least
equivalent to tamoxifen [1], whereas in the second study, anas-
trozole signiﬁcantly improved TTP vs. tamoxifen [2]. However,
neither study evaluated efﬁcacy speciﬁcally in the subgroup of
patients with de novo advanced breast cancer or those who were
truly endocrine therapy-naïve.
The efﬁcacy of exemestane vs. tamoxifen as ﬁrst-line treatment
was investigated in a phase III open-label study [3]. Progression-
free survival (PFS) ﬁndings favored exemestane over tamoxifen
overall and in patients who had not received prior hormonal
treatment. Furthermore, exploratory analyses suggested that pre-
vious hormonal therapy was not a prognostic factor for PFS.
Several studies evaluated fulvestrant as ﬁrst-line therapy. In a
double-blind study, no differences in TTP between fulvestrant
250 mg (the previous recommended dose) and tamoxifen treat-
ment were seen [4]. Furthermore, no difference was observed be-
tween patients who had received prior adjuvant tamoxifen
treatment and the overall population (unpublished data).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Randomized clinical studies in post-menopausal patients with locally advanced or metastatic breast cancer identiﬁed in the literature review.
Study design Patient population Receptor status Treatment Endocrine therapy Overall ﬁndings
Phase III, randomized,
double-blind,
multicenter study
(TARGET) [1]
Post-menopausal women with
locally advanced or metastatic
breast cancer (N ¼ 668)
Patients with hormone
receptor-positive (ERþ and/or
PgRþ) tumors or tumors of
unknown status were included
HER2þ patients were not
excluded
ERþ, PgRþ: 24e26%
ERþ, PgR: 8e9%
Anastrozole 1 mg vs.
tamoxifen 20 mg
Patients had to be eligible for ﬁrst-line treatment
with endocrine therapy
Prior adjuvant chemotherapy or endocrine therapy
for early disease was permitted. Tamoxifen
treatment was not permitted within 12 months
prior to study entry
69e70% of patients had not received prior adjuvant
therapy
6e9% had received prior adjuvant endocrine
therapy only
3e5% had received adjuvant endocrine therapy plus
cytotoxic therapy
TTP
Anastrozole: 8.2 months
Tamoxifen: 8.3 months
(HR 0.99; lower 95% CI 0.86; 2-sided
p ¼ 0.941)
OR
Anastrozole: 32.9%
Tamoxifen: 32.6%
(2-sided p ¼ 0.787)
OS, not reported
Phase III, randomized,
double-blind,
multicenter study
(TARGET) [2]
Post-menopausal women with
locally advanced or metastatic
breast cancer (N ¼ 353)
Patients with hormone
receptor-positive (ERþ and/or
PgRþ) tumors or tumors of
unknown status were included
HER2þ patients were not
excluded
ERþ, PgRþ: 64e67%
ERþ, PgR: 17e19%
Anastrozole 1 mg vs.
tamoxifen 20 mg
Patients had to be eligible for ﬁrst-line treatment
with endocrine therapy
Prior adjuvant chemotherapy or endocrine therapy
for early disease was permitted. Tamoxifen
treatment was not permitted within 12 months
prior to study entry
60e61% of patients had not received prior adjuvant
therapy
11e12% of patients had received adjuvant
endocrine therapy only
7e9% had received adjuvant endocrine therapy plus
cytotoxic therapy
TTP
Anastrozole: 11.1 months
Tamoxifen: 5.6 months
(HR 1.44; lower 95% CI 1.16; 2-sided
p ¼ 0.005)
OR
Anastrozole: 21.1%
Tamoxifen: 17.0%
OS, not reported
Phase III, randomized,
open-label, multicenter
study (EORTC) [3]
Post-menopausal women with
hormone-sensitive metastatic
or locally recurrent breast
cancer (N ¼ 382)
Primary tumors or metastases
had to be hormone receptor-
positive. Patients with tumors
of unknown status were
included
HER2þ patients were not
excluded
ERþ, PgRþ: 57%
ERþ, PgR: 25%
Exemestane 25 mg vs.
tamoxifen 20 mg
Previous hormone therapy for metastatic breast
cancer was not allowed; however, patients were
permitted to have received prior treatment with
adjuvant tamoxifen
42% of patients had received prior systemic therapy
10% had received prior hormonal therapy only
11% had received adjuvant endocrine therapy plus
cytotoxic therapy
PFS
Exemestane: 9.9 months
Tamoxifen: 5.8 months
(HR 0.84; 95% CI 0.67, 1.05; log-rank
p ¼ 0.121; Wilcoxon p ¼ 0.028)
OR
Exemestane: 46%
Tamoxifen: 31%
(p ¼ 0.005)
OS
Exemestane: 37.2 months
Tamoxifen: 43.3 months
(log-rank p ¼ 0.821)
Randomized, double-blind,
multicenter study [4]
Post-menopausal women with
locally advanced or metastatic
breast cancer (N ¼ 587)
Patients with hormone
receptor-positive (ERþ and/or
PgRþ) tumors or tumors of
unknown status were included
HER2þ patients were not
excluded
ERþ, PgRþ: 42%
ERþ, PgR: 16e19%
Fulvestrant 250 mga vs.
tamoxifen 20 mg
Previous endocrine therapy for advanced breast
cancer was not allowed
No adjuvant endocrine therapy (tamoxifen) was
allowed within 12 months of study entry
22e25% had received prior endocrine therapy
(tamoxifen)
TTP
Fulvestrant: 6.8 months
Tamoxifen: 8.3 months
(HR 1.18; 95% CI 0.98, 1.44; p ¼ 0.088)
OR
Fulvestrant: 31.6%
Tamoxifen: 33.9% (p ¼ 0.45)
OS
Fulvestrant: 36.9 months
Tamoxifen: 38.7 months
(HR 1.29; 95% CI 1.01, 1.64; p ¼ 0.04)
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Phase II, randomized, open-
label, parallel-group,
multicenter study
(FIRST) [5e7]
Post-menopausal women with
locally advanced or metastatic
breast cancer (N ¼ 205)
Patients with hormone
receptor-positive (ERþ and/or
PgRþ) tumors
HER2þ patients were not
excluded
ERþ, PgRþ: 76e77%
ERþ, PgR: 18e19%
Fulvestrant 500 mgb vs.
anastrozole 1 mg
Prior endocrine therapy for advanced disease was
not permitted
Adjuvant endocrine therapy for early disease was
allowed if completed >12 months prior to study
75% of patients had not received prior endocrine
therapy
CBR
Fulvestrant: 72.5%
Anastrozole: 67.0%
(p ¼ 0.386)
TTP
Fulvestrant: 23.4 months
Anastrozole: 13.1 months
(HR 0.66; 95% CI 0.47, 0.92; p ¼ 0.01)
OS
Fulvestrant: 54.1 months
Anastrozole: 48.4 months
(HR 0.70; 95% CI 0.50, 0.98; p ¼ 0.04)
No prior endocrine therapy
HR 0.63; 95% CI 0.42, 0.93
Prior endocrine therapy
HR 1.01; 95% CI 0.51, 1.99
Phase III, randomized,
open-label, parallel-
group, multicenter study
(FACT) [8]
Post-menopausal or
premenopausal women with
breast cancer with relapse
during/after primary treatment
(N ¼ 514)
Patients with hormone
receptor-positive (ERþ and/or
PgRþ) tumors
ERþ, PgRþ: 75e76%
ERþ, PgR: 20e23%
Fulvestrant
250 mg þ LDc in
combination with
anastrozole 1 mg vs.
anastrozole 1 mg alone
Patients could have received prior adjuvant
endocrine therapy, chemotherapy, or radiotherapy
30e34% of patients had not received prior
endocrine therapy
TTP
Anastrozole and fulvestrant: 10.8
months
Anastrozole alone: 10.2 months
(HR 0.99; 95% CI 0.81, 1.20; p ¼ 0.91)
OR
Anastrozole and fulvestrant: 31.8%
Anastrozole alone: 33.6%
(p ¼ 0.76)
OS
Anastrozole and fulvestrant: 37.8
months
Anastrozole alone: 38.2 months
(HR 1.00; 95% CI 0.76, 1.32; p ¼ 1.0)
Phase II, randomized, open-
label, multicenter study
(PALOMA-1/TRIO-18) [9]
Post-menopausal women with
locally recurrent or metastatic
breast cancer (N ¼ 165)
ERþ: 100%
HER2þ patients were excluded
Palbociclib 125 mg plus
letrozole 2.5 mg vs.
letrozole 2.5 mg alone
Patients were not permitted to receive prior
treatment for advanced breast cancer
Patients could receive prior systemic hormonal
treatment for early disease
46e52% of patients had not received previous
systemic treatment
32e35% of patients had received prior adjuvant
endocrine therapy
PFS
Palbociclib plus letrozole: 20.2 months
Letrozole alone: 10.2 months
(HR 0.488; 95% CI 0.319, 0.748; 1-sided
p ¼ 0.0004)
No prior endocrine therapy
HR 0.397; 95% CI 0.244, 0.646
Prior endocrine therapy
HR 0.460; 95% CI 0.222, 0.956
OR
Palbociclib plus letrozole: 43%
Letrozole alone: 33%
(p ¼ 0.13)
OS
Palbociclib plus letrozole: 37.5 months
Letrozole alone: 33.3 months
(HR 0.813; 95% CI 0.492, 1.345; 2-sided
p ¼ 0.42)
Phase III, randomized,
open-label, multicenter
study (LEA) [10]
Post-menopausal patients with
advanced breast cancer
(N ¼ 380)
Hormone receptor-positive:
100%
HER2þ patients were excluded
Bevacizumab (15 mg/
kg) plus endocrine
therapy (letrozole
2.5 mg or fulvestrant
250 mga) vs. endocrine
therapy alone
Prior treatment for metastatic disease was not
permitted
52% of patients had received prior endocrine
therapy
PFS
Bevacizumab plus endocrine therapy:
19.3 months
Endocrine therapy alone: 14.4 months
(HR 0.83; 95% CI 0.65, 1.06; log-rank
p ¼ 0.126)
(continued on next page)
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Table 1 (continued )
Study design Patient population Receptor status Treatment Endocrine therapy Overall ﬁndings
OR
Bevacizumab plus endocrine therapy:
40.8%
Endocrine therapy alone: 21.9%
(p < 0.001)
OS
Bevacizumab plus endocrine therapy:
52.1 months
Endocrine therapy alone: 51.8 months
(HR 0.87; 95% CI 0.58, 1.32; log-rank
p ¼ 0.518)
Phase III, randomized,
open-label study (CALGB
40503 Alliance) [11]
Patients with advanced breast
cancer (N ¼ 350)
Hormone receptor-positive:
100%
Bevacizumab (15 mg/
kg) plus letrozole
2.5 mg vs. letrozole
2.5 mg alone
NA PFS
Bevacizumab plus letrozole: 20 months
Letrozole: 16 months
(HR 0.74; 95% CI 0.58, 0.95; p ¼ 0.016)
OS
Bevacizumab plus letrozole: 47 months
Letrozole: 41 months
(HR 0.84; 95% CI 0.61, 1.15; p ¼ 0.27)
Phase III, randomized,
double-blind,
multicenter study
(International Letrozole
Breast Cancer Group
study) [12,16]
Post-menopausal patients with
locally advanced or metastatic
breast cancer (N ¼ 907)
Patients with hormone
receptor-positive (ERþ and/or
PgRþ) tumors or tumors of
unknown status were included
HER2þ patients were not
excluded
ERþ and/or PgRþ: 65e67%
Letrozole 2.5 mg vs.
tamoxifen 20 mg
Patients could receive one regimen of
chemotherapy for advanced disease provided they
had disease progression within 3 months before
study start
Prior adjuvant endocrine therapy for advanced
disease with the exception of antiestrogens was not
permitted
81e82% of patients had not received adjuvant
antiestrogen therapy
TTP
Letrozole: 9.4 months
Tamoxifen: 6.0 months
(HR 0.70; 95% CI 0.60, 0.82; p ¼ 0.0001)
Prior adjuvant antiestrogen therapy
yes:no
(HR 1.13; 95% CI 0.93, 1.38; p ¼ 0.2)
OR
Letrozole: 30%
Tamoxifen: 20%
(p ¼ 0.0006)
OS
Letrozole: 34 months
Tamoxifen: 30 months
(p ¼ 0.53)
Phase III randomized study
[14]
Post-menopausal women with
metastatic breast cancer
(N ¼ 707)
Patients with hormone
receptor-positive (ERþ and/or
PgRþ) tumors
ERþ and/or PgRþ: 100%
HER2þ: 10%
Fulvestrant
250 mg þ LDc in
combination with
anastrozole 1 mg vs.
anastrozole 1 mg alone
Previous hormone therapy for metastatic breast
cancer was not allowed
Adjuvant endocrine therapy for early disease was
allowed if it was completed >12 months prior to
enrollment
60% of patients had not received prior adjuvant
tamoxifen
PFS
Anastrozole and fulvestrant: 15.0
months
Anastrozole alone: 13.5 months
(HR 0.80; 95% CI 0.68, 0.94; log-rank
p ¼ 0.007)
No prior tamoxifen: HR 0.74; 95% CI
0.59, 0.92; log-rank p ¼ 0.006
Prior tamoxifen
HR 0.89; 95% CI 0.69, 1.15; log-rank
p ¼ 0.37)
OR
Anastrozole and fulvestrant: 27%
Anastrozole alone: 22%
(p ¼ 0.26)
OS
Anastrozole and fulvestrant: 47.7
months
Anastrozole alone: 41.3 months
(HR 0.81; 95% CI 0.65, 1.00; 2-sided
p ¼ 0.049)
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500 mg (the current recommended dose) vs. anastrozole [5]. Ful-
vestrant 500 mg was at least as effective at anastrozole in terms of
clinical beneﬁt rate [5], and in a follow-up analysis, increased TTP
vs. anastrozole [6]. In the overall population, fulvestrant 500 mg
improved overall survival (OS) vs. anastrozole [7]. In subgroup
analyses, OS was increased with fulvestrant 500 mg vs. anastrozole
for endocrine therapy-naïve patients, but was equivalent between
treatments for patients who had received prior endocrine therapy.
Combination treatment of anastrozole and a fulvestrant 250 mg
plus loading dose regimenwas compared with anastrozole alone in
a phase III open-label study [8]. TTP was no different between
treatment arms; this treatment effect was also apparent in patients
who had not received prior endocrine therapy.
A phase II, open-label study evaluated the efﬁcacy of palbociclib
in combination with letrozole vs. letrozole alone. PFS was signiﬁ-
cantly improved with the combination compared with letrozole.
Multivariate analysis demonstrated that an effect consistent with
the overall analysis was observed for patients with and without
prior hormonal treatment [9].
A recent phase III, open-label trial evaluated bevacizumab plus
endocrine therapy (letrozole or fulvestrant 250 mg) vs. endocrine
therapy alone as ﬁrst-line treatment [10]. PFS was not statistically
signiﬁcantly different between treatment groups. In a multivariate
analysis, previous endocrine therapy and type of endocrine therapy
were independent prognostic factors for PFS. A second phase III,
open-label study evaluated bevacizumab plus letrozole vs. letrozole
alone as ﬁrst-line treatment. Preliminary results demonstrated that
the combination signiﬁcantly improved PFS vs. letrozole alone,
although a subgroup analysis for patients with and without prior
adjuvant endocrine therapy has not been reported [11].
First-line treatment with letrozole had superior efﬁcacy over
tamoxifen in a phase III, double-blind study. In a multivariate
analysis, prior adjuvant therapy with antiestrogens did not impact
on TTP vs. no adjuvant therapy, and letrozole superiority over
tamoxifen was maintained [12].
Patients with de novo metastatic breast cancer accounted for
approximately 6% of all cases at diagnosis in an analysis of records
from two US cancer centers [13]. However, data on the effectiveness
of ﬁrst-line endocrine therapy in patients with de novo metastatic
breast cancer are very limited. In one study, PFS was signiﬁcantly
longer with fulvestrant 250 mg plus anastrozole vs. anastrozole
alone, and was not signiﬁcantly affected by use of prior adjuvant
tamoxifen therapy [14]. Results of a phase III study suggested that
letrozole in combination with lapatinib, a dual tyrosine kinase in-
hibitor, was associated with signiﬁcantly longer PFS vs. letrozole
alone overall and in patients with human epidermal growth factor
receptor (HER) 2-positive disease (but not in patients with HER2-
negative disease) [15].
Discussion
Our literature review demonstrates that there is a paucity of
clinical studies in the speciﬁc population of patients with endocrine
therapy-naïve, hormone receptor-positive advanced or metastatic
breast cancer. Most evidence in these patients was obtained from
subgroup analyses of overall study populations that were not pre-
planned or powered speciﬁcally for these comparisons; this
inherently limits meaningful interpretation of ﬁndings. However,
where sub-analyses have been conducted, it generally appears that
ﬁrst-line treatment effects are consistent between patients who
have and have not received prior endocrine treatment. Further-
more, inherent differences in tumor biology between de novo
metastatic disease and recurrent disease, and heterogeneity in the
patient populations within the studies reviewed (including HER2-
M. Martin et al. / The Breast 28 (2016) 161e166166positive status) may inﬂuence sensitivity to treatment and limit the
conclusions that can be drawn. Collectively, this highlights the need
for clinical trials to deﬁnitively evaluate the role of selective
endocrine treatment in patients with endocrine therapy-naïve
disease.
The phase III, randomized, double-blind, parallel-group FALCON
study (NCT01602380) is comparing the efﬁcacy and tolerability of
fulvestrant 500 mg with anastrozole as ﬁrst-line treatment in post-
menopausal patients with hormone receptor-positive advanced
breast cancer, speciﬁcally in patients who have not received any
prior endocrine therapy. Data are expected to report in 2016 for
FALCON and are awaited with interest.
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